Stockscreener 앱 받기
108.00
0.85%
0.955
전일 마감가:
$107.05
열려 있는:
$106.86
하루 거래량:
45,987
Relative Volume:
0.08
시가총액:
$8.39B
수익:
-
순이익/손실:
$-224.29M
주가수익비율:
-27.69
EPS:
-3.9
순현금흐름:
$-185.06M
1주 성능:
-1.27%
1개월 성능:
+17.23%
6개월 성능:
+38.25%
1년 성능:
+15.18%
1일 변동 폭
$106.86
$109.04
1주일 범위
$103.51
$109.04
52주 변동 폭
$55.53
$112.88
Nuvalent Inc Stock (NUVL) Company Profile
명칭
Nuvalent Inc
전화
508-446-2272
주소
ONE BROADWAY, 14TH FLOOR, CAMBRIDGE
NUVL을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
NUVL
Nuvalent Inc
|
108.03 | 8.30B | 0 | -224.29M | -185.06M | -3.90 |
|
VRTX
Vertex Pharmaceuticals Inc
|
458.70 | 116.04B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
729.43 | 75.97B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
462.33 | 61.48B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
904.45 | 56.40B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
204.81 | 43.73B | 447.02M | -1.18B | -906.14M | -6.1812 |
Nuvalent Inc Stock (NUVL) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-11-24 | 개시 | Truist | Buy |
| 2025-11-12 | 개시 | Canaccord Genuity | Buy |
| 2025-10-16 | 재개 | Stifel | Buy |
| 2025-10-15 | 개시 | Cantor Fitzgerald | Overweight |
| 2025-09-04 | 재개 | Guggenheim | Buy |
| 2025-09-03 | 개시 | Raymond James | Outperform |
| 2025-08-19 | 개시 | Piper Sandler | Overweight |
| 2025-03-14 | 업그레이드 | UBS | Neutral → Buy |
| 2024-12-30 | 개시 | H.C. Wainwright | Buy |
| 2024-10-24 | 개시 | UBS | Neutral |
| 2024-08-29 | 개시 | Barclays | Overweight |
| 2024-04-17 | 개시 | Jefferies | Buy |
| 2024-04-01 | 업그레이드 | Leerink Partners | Market Perform → Outperform |
| 2024-02-28 | 재개 | Guggenheim | Buy |
| 2024-02-23 | 개시 | Robert W. Baird | Outperform |
| 2023-09-27 | 개시 | Stifel | Buy |
| 2023-08-08 | 개시 | SVB Securities | Market Perform |
| 2023-07-24 | 개시 | Guggenheim | Buy |
| 2023-01-18 | 개시 | Wedbush | Outperform |
| 2022-06-24 | 개시 | BMO Capital Markets | Outperform |
모두보기
Nuvalent Inc 주식(NUVL)의 최신 뉴스
Russell Investments Group Ltd. Sells 28,747 Shares of Nuvalent, Inc. $NUVL - MarketBeat
Rhumbline Advisers Has $5.04 Million Stock Holdings in Nuvalent, Inc. $NUVL - MarketBeat
Layoff Watch: Is Nuvalent Inc stock trading at a premium valuationEarnings Growth Summary & Free Expert Verified Stock Movement Alerts - BỘ NỘI VỤ
NUVL: Late-stage oncology assets show strong efficacy and safety, with first approvals targeted for 2026 - TradingView
Will Nuvalent Inc. stock attract more institutional investorsMarket Sentiment Summary & Long-Term Safe Investment Ideas - Newser
Nuvalent Insider Sold Shares Worth $434,319, According to a Recent SEC Filing - marketscreener.com
American Century Companies Inc. Boosts Holdings in Nuvalent, Inc. $NUVL - MarketBeat
Creative Planning Buys 9,079 Shares of Nuvalent, Inc. $NUVL - MarketBeat
(NUVL) Volatility Zones as Tactical Triggers - news.stocktradersdaily.com
Returns Recap: Is Nuvalent Inc. stock trading near support levelsJuly 2025 Volume & Long Hold Capital Preservation Tips - BỘ NỘI VỤ
Nuvalent to Participate in the Piper Sandler 37th Annual Healthcare Conference - Eastern Progress
Does Nuvalent’s Recent Trial Success Justify the Stock’s 36% 2025 Rally? - Yahoo Finance
Nuvalent Highlights Pipeline and Business Achievements, Reiterates Key Anticipated Milestones, and Reports Second Quarter 2025 Financial Results (PR Newswire) - Aktiellt
Nuvalent to Participate in the Piper Sandler 37th Annual Healthc - GuruFocus
Universal Beteiligungs und Servicegesellschaft mbH Sells 14,688 Shares of Nuvalent, Inc. $NUVL - MarketBeat
Nuvalent: Deerfield funds sell $70.8m in NUVL stock By Investing.com - Investing.com South Africa
Nuvalent (NUVL) Receives a New Rating from Truist Financial - The Globe and Mail
Nuvalent’s Cash Cushion Keeps Investors On Board Through Setbacks - Finimize
Nuvalent Announces Closing of Public Offering of Common Stock and Full Exercise by Underwriters of Option to Purchase Additional Shares from Selling Stockholders - Finviz
Nuvalent: Deerfield funds sell $70.8m in NUVL stock - Investing.com
Nuvalent closes $500 million public offering of common stock By Investing.com - Investing.com South Africa
Nuvalent Announces Closing of Public Offering of Common Stock an - GuruFocus
Nuvalent Closes Public Offering of Common Shares - marketscreener.com
Nuvalent closes $500 million public offering of common stock - Investing.com
Nuvalent (NASDAQ: NUVL) closes $500M stock offering; 4,950,496 shares sold in public deal - Stock Titan
Nuvalent announces public offering of common stock - MSN
FDA accepts NDA for Nuvalent's zidesamtinib for non-small cell lung cancer - MSN
J.P. Morgan Sticks to Its Buy Rating for Nuvalent (NUVL) - The Globe and Mail
Four companies raise nearly $950M in follow-ons: Public Equity Report - BioCentury
Nuvalent Announces $500M Stock Offering Pricing - The Globe and Mail
Biotech Stock Gets Booted in Latest Fund Update - AOL.com
Will Nuvalent Inc. stock keep outperforming rivalsJuly 2025 Chart Watch & Advanced Swing Trade Entry Alerts - newser.com
Why analysts upgrade Nuvalent Inc. stockJuly 2025 Weekly Recap & Technical Pattern Based Buy Signals - newser.com
Sidley Represents Nuvalent in Pricing of US$500 Million Public Offering - Legal Desire Media and Insights
Jefferies raises Nuvalent stock price target to $164 on promising cancer drug data - Investing.com Nigeria
[8-K] Nuvalent, Inc. Reports Material Event | NUVL SEC FilingForm 8-K - Stock Titan
Nuvalent Announces FDA Acceptance of New Drug Application for Zidesamtinib for the Treatment of TKI Pre-treated Patients with Advanced ROS1-positive NSCLC - The Malaysian Reserve
Can Nuvalent Inc. stock surprise with earnings upsideWeekly Trade Report & Safe Capital Growth Plans - newser.com
Will Nuvalent Inc. stock reach Wall Street targetsPortfolio Return Report & Accurate Buy Signal Notifications - newser.com
FDA accepts Nuvalent’s zidesamtinib application for lung cancer treatment By Investing.com - Investing.com Nigeria
Nuvalent Insider Sold Shares Worth $2,065,030, According to a Recent SEC Filing - MarketScreener
Nuvalent Gets FDA Review of Zidesamtinib for ROS1-Positive Lung Cancer - marketscreener.com
FDA accepts Nuvalent’s zidesamtinib application for lung cancer treatment - Investing.com
Nuvalent Inc (NUVL) 재무 분석
매출
순이익
현금흐름
주당 순 이익
Nuvalent Inc 주식 (NUVL) 내부자 거래
| 내부자 거래 | 관계 | 날짜 | 거래 | 비용 | #주식 | 가치 ($) | #주식 총계 |
|---|---|---|---|---|---|---|---|
| Noci Darlene | Chief Development Officer |
Nov 28 '25 |
Sale |
108.58 |
4,000 |
434,319 |
48,034 |
| Shair Matthew | Director |
Nov 24 '25 |
Sale |
109.37 |
5,850 |
639,814 |
1,377,194 |
| Shair Matthew | Director |
Nov 24 '25 |
Sale |
109.37 |
1,650 |
180,460 |
201,672 |
| Flynn James E | Director by Deputization |
Nov 24 '25 |
Sale |
95.44 |
742,574 |
70,874,975 |
8,299,225 |
| Balcom Alexandra | Chief Financial Officer |
Nov 17 '25 |
Option Exercise |
49.85 |
20,000 |
996,962 |
81,734 |
| Balcom Alexandra | Chief Financial Officer |
Nov 18 '25 |
Option Exercise |
72.35 |
729 |
52,743 |
62,463 |
| Balcom Alexandra | Chief Financial Officer |
Nov 17 '25 |
Sale |
99.45 |
20,000 |
1,989,025 |
61,734 |
| Balcom Alexandra | Chief Financial Officer |
Nov 18 '25 |
Sale |
104.26 |
729 |
76,005 |
61,734 |
| Miller Deborah Ann | Chief Legal Officer |
Nov 17 '25 |
Option Exercise |
6.89 |
24,200 |
166,738 |
73,286 |
| Miller Deborah Ann | Chief Legal Officer |
Nov 17 '25 |
Sale |
105.50 |
24,200 |
2,552,999 |
49,086 |
0.29%
0.67%
자본화:
|
볼륨(24시간):